title: Effects of growth hormone and pioglitazone in viscerally obese adults with impaired glucose tolerance: a factorial clinical trial.
abstract: OBJECTIVE
  Recombinant human growth hormone (GH) and pioglitazone (PIO) in abdominally obese adults with impaired glucose tolerance were evaluated under the hypothesis that the combination attenuates GH-induced increases in glucose concentrations, reduces visceral adipose tissue (VAT), and improves insulin sensitivity over time.
  
  
  METHODS
  Randomized, double-blind, placebo-controlled, 2 x 2 factorial design.
  
  
  METHODS
  Veterans Affairs Palo Alto Health Care System, Palo Alto, California, United States.
  
  
  METHODS
  62 abdominally obese adults aged 40-75 with impaired glucose tolerance.
  
  
  METHODS
  GH (8 microg/kg/d, or placebo) and pioglitazone (30 mg/d, or placebo) for 40 wk.
  
  
  METHODS
  Baseline and after 40 wk of treatment, VAT content was quantified by CT scan, glucose tolerance was assessed using a 75-g oral glucose tolerance test, and insulin sensitivity was measured using steady-state plasma glucose levels obtained during insulin suppression test.
  
  
  RESULTS
  BASELINE: body mass index (BMI), plasma glucose, and visceral fat content were similar. 40 wk: visceral fat area declined 23.9 +/- 7.4 cm(2) in GH group, mean difference from placebo: -28.1 cm(2) (95% CI -49.9 to -6.3 cm(2); p = 0.02). Insulin resistance declined 52 +/- 11.8 mg/dl with PIO, mean difference from placebo of -58.8 mg/dl (95% CI -99.7 to -18.0 mg/dl; p = 0.01). VAT and SSPG declined with GH and PIO combined, mean differences from placebo of -31.4 cm(2) (95% CI -56.5 cm(2) to -6.3 cm(2); p = 0.02) and -55.3 mg/dl (95% CI -103.9 to -6.7 mg/dl; p = 0.02), respectively. Fasting plasma glucose increased transiently in GH group. No significant changes in BMI were observed.
  
  
  CONCLUSIONS
  Addition of PIO to GH attenuated the short-term diabetogenic effect of GH; the drug combination reduced VAT and insulin resistance over time. GH plus PIO may have added benefit on body composition and insulin sensitivity in the metabolic syndrome.
authors.affiliation: Department of Medicine, Wayne State University, Detroit, Michigan, United States of America.
authors.forename: Hamdee
authors.initials: H
authors.lastname: Attallah
authors.forename: Anne L
authors.initials: AL
authors.lastname: Friedlander
authors.forename: Matilde
authors.initials: M
authors.lastname: Nino-Murcia
authors.forename: Andrew R
authors.initials: AR
authors.lastname: Hoffman